Abstract | BACKGROUND AND AIMS: MATERIALS AND METHODS: In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. Blood samples were drawn 1, 3, and 5 days after vaccination and were tested for HBsAg using two different ELISA kits (Behring and Mega). RESULTS:
HBsAg was positive in 5, 3, and 2 participants of the Engerix-B group in the 1st, 3rd, and 5th days after vaccination, respectively, using the Behring ELISA kit the test was positive in only one subject in the Hepavax-Gene group, on the 5th day after vaccination. No positive result was seen in any groups when the Mega ELISA kit was used to test the specimens. CONCLUSIONS: Our results showed transient HBsAg antigenemia after vaccination against hepatitis B. This condition depends on the type of vaccine and the HBsAg diagnostic test.
|
Authors | Masoud Ziaee, Alireza Saádatjoo, Malihe Mohamadpour, Mohammad Hasan Namaei |
Journal | Hepatitis monthly
(Hepat Mon)
Vol. 10
Issue 4
Pg. 298-301
( 2010)
ISSN: 1735-3408 [Electronic] Netherlands |
PMID | 22312397
(Publication Type: Journal Article)
|